RT Journal Article
SR Electronic
T1 Atrial Natriuretic Peptide and Long Acting Natriuretic Peptide Inhibit MEK 1/2 Activation in Human Prostate Cancer Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3813
OP 3818
VO 27
IS 6B
A1 SUN, YING
A1 EICHELBAUM, EHRENTRAUD J.
A1 WANG, HAI
A1 VESELY, DAVID L.
YR 2007
UL http://ar.iiarjournals.org/content/27/6B/3813.abstract
AB Background: Atrial natriuretic peptide and long acting natriuretic peptide have anticancer effects in human prostate adenocarcinomas. Materials and Methods: Atrial natriuretic peptide, long acting natriuretic peptide and cyclic GMP's effects on MEK 1/2 kinase were examined in human prostate adenocarcinoma cells. Results: Atrial natriuretic peptide and long acting natriuretic peptide decreased the activation of MEK 1/2 over a concentration range of 0.01 μM to 10 μM. Long acting natriuretic peptide and atrial natriuretic peptide (each 10 μM) inhibited the phosphorylation of MEK 1/2 kinase 97% (p<0.00001) and 88% (p<0.00001), respectively. The inhibition of MEK 1/2 was maximal at two hours, and ceased by four hours, secondary to both peptides. The ability of peptides to inhibit MEK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited MEK 1/2 phosphorylation by 93%. Conclusion: Atrial natriuretic peptide and long acting natriuretic peptide both inhibit MEK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved